KIM-1 antibodies for treatment of TH2-mediated conditions
View Patent ↗Compositions and methods for treating Th2- and ThI-mediated disease are provided.
1. A method of treating a Th2-mediated disorder, the method comprising administering to a mammal having a Th2-mediated disorder an antibody, or antigen-binding fragment thereof, that binds the sialic acid binding motif of KIM-1 at an epitope contained within amino acids 81-107 of SEQ ID NO:1.
2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof protects a TPCK trypsin site within amino acids 81-107 of SEQ ID NO:1.
3. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof interferes with one or more of residues R86, W92, and F93 of SEQ ID NO:1.
4. The method of claim 1 , wherein the mammal is a human.
5. The method of claim 1 , wherein the disorder is atopy.
6. The method of claim 1 , wherein the disorder is asthma.
7. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
8. The method of claim 1 , wherein a full-length antibody is administered.
9. The method of claim 1 , wherein an antigen-binding fragment of the antibody is administered.
10. The method of claim 9 , wherein the antigen-binding fragment is selected from the group consisting of a single chain antibody, an Fab fragment, an F(ab′)2 fragment, an Fd fragment, an Fv fragment, and a dAb fragment.
11. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is administered in combination with a second therapeutic agent for the disorder.
12. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is administered at a dosage between 0.05 and 20 mg/kg.
13. The method of claim 6 , wherein the asthma is allergic asthma.
14. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is a fully human monospecific antibody or antigen-binding fragment thereof.
15. The method of claim 4 , wherein the disorder is atopy.
16. The method of claim 4 , wherein the disorder is asthma.
17. The method of claim 16 , wherein the asthma is allergic asthma.
18. The method of claim 4 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
19. The method of claim 4 , wherein the antibody or antigen-binding fragment thereof is a fully human monospecific antibody or antigen-binding fragment thereof.
20. The method of claim 4 , wherein a full-length antibody is administered.
21. The method of claim 4 , wherein an antigen-binding fragment of the antibody is administered.
22. The method of claim 21 , wherein the antigen-binding fragment is selected from the group consisting of a single chain antibody, an Fab fragment, an F(ab′)2 fragment, an Fd fragment, an Fv fragment, and a dAb fragment.
23. The method of claim 15 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
24. The method of claim 15 , wherein the antibody or antigen-binding fragment thereof is a fully human monospecific antibody or antigen-binding fragment thereof.
25. The method of claim 15 , wherein a full-length antibody is administered.
26. The method of claim 15 , wherein an antigen-binding fragment of the antibody is administered.
27. The method of claim 26 , wherein the antigen-binding fragment is selected from the group consisting of a single chain antibody, an Fab fragment, an F(ab′)2 fragment, an Fd fragment, an Fv fragment, and a dAb fragment.
28. The method of claim 16 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
29. The method of claim 16 , wherein the antibody or antigen-binding fragment thereof is a fully human monospecific antibody or antigen-binding fragment thereof.
30. The method of claim 16 , wherein a full-length antibody is administered.
31. The method of claim 16 , wherein an antigen-binding fragment of the antibody is administered.
32. The method of claim 31 , wherein the antigen-binding fragment is selected from the group consisting of a single chain antibody, an Fab fragment, an F(ab′)2 fragment, an Fd fragment, an Fv fragment, and a dAb fragment.
33. The method of claim 17 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
34. The method of claim 17 , wherein the antibody or antigen-binding fragment thereof is a fully human monospecific antibody or antigen-binding fragment thereof.
35. The method of claim 17 , wherein a full-length antibody is administered.
36. The method of claim 17 , wherein an antigen-binding fragment of the antibody is administered.
37. The method of claim 36 , wherein the antigen-binding fragment is selected from the group consisting of a single chain antibody, an Fab fragment, an F(ab′)2 fragment, an Fd fragment, an Fv fragment, and a dAb fragment.